Breast cancer screening test

Indicaton

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening.
The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases.
Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Therapeutic indications

Type of product

Table

Phase

Phase II completed
Partnering status

Not partnered

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started

SOT109 (Antibody-Drug Conjugate)

solid tumors, mainly colorectal

Discovery